GABELLI & Co INVESTMENT ADVISERS INC. Acquires Shares of 418,950 Kenvue Inc. $KVUE

GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 418,950 shares of the company’s stock, valued at approximately $7,227,000. Kenvue comprises approximately 1.1% of GABELLI & Co INVESTMENT ADVISERS INC.’s holdings, making the stock its 24th largest holding.

Other hedge funds have also made changes to their positions in the company. NBT Bank N A NY boosted its stake in shares of Kenvue by 180.3% during the third quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after buying an additional 1,006 shares during the period. Cornerstone Planning Group LLC boosted its stake in shares of Kenvue by 705.2% during the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock worth $25,000 after buying an additional 1,361 shares during the period. Physician Wealth Advisors Inc. boosted its stake in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the period. Elyxium Wealth LLC acquired a new stake in shares of Kenvue during the fourth quarter worth about $26,000. Finally, Golden State Wealth Management LLC boosted its stake in shares of Kenvue by 150.1% during the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock worth $32,000 after buying an additional 1,190 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Citigroup decreased their target price on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 8th. UBS Group decreased their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Canaccord Genuity Group lifted their target price on shares of Kenvue from $17.00 to $18.00 and gave the company a “hold” rating in a report on Wednesday, February 18th. Finally, Jefferies Financial Group downgraded shares of Kenvue from a “buy” rating to a “hold” rating and lowered their target price for the company from $23.00 to $18.00 in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $19.33.

Insider Buying and Selling

In related news, General Counsel Matthew Orlando sold 38,491 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total transaction of $679,751.06. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.59% of the company’s stock.

Kenvue Stock Down 0.1%

Shares of NYSE:KVUE opened at $17.09 on Monday. The company has a market cap of $32.81 billion, a price-to-earnings ratio of 20.10, a PEG ratio of 1.30 and a beta of 0.55. The firm’s 50-day simple moving average is $17.48 and its 200-day simple moving average is $17.33. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $24.35.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.05. The business had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.24 earnings per share. As a group, equities research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th will be issued a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.9%. Kenvue’s payout ratio is currently 97.65%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.